Please assess the completion status of the following clinical trial:

Trial Title: A Study of Effectiveness and Safety of Paliperidone Extended-release (ER) Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV diagnosis of schizophrenia at least 1 year before screening~* experiencing an acute schizophrenic episode with a total PANSS score between 70 and 120~* agree to be hospitalized for a minimum of 14 days at the start of the study~* capable of administering study medication themselves or have assistance with study medication administration consistently available throughout the study~* resided at the same address continuously for at least 30 days prior to screening~* able and willing to fill out self administered questionnaires~* washout of antiparkinsonian medications, beta-blockers~* antiepileptics, lithium 3 days prior to the start of the run-in phase~Exclusion Criteria:~* DSM-IV Axis I diagnosis other than schizophrenia~* DSM-IV diagnosis of substance dependence within 6 months prior to screening (nicotine and caffeine dependence are not exclusionary)~* preexisting severe gastrointestinal narrowing (pathologic or iatrogenic)~* injection of a depot antipsychotic within 120 days before screening, or use of paliperidone palmitate within 10 months before screening~* previous history of lack of response to risperidone when acutely psychotic~* history of neuroleptic malignant syndrome~* significant risk of suicidal or violent behavior

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).